[Case study of 14C-labelled lecithin placental transfer].
Because of the clinical and biochemical state of a 26 years old patient an erythroblastosis was expected. Continuous controls revealed that delivery in the 36th week of pregnancy was necessary. A therapeutic research with lecithine through the maternal circulation in this special case was carried out in order to prevent a respiratory distress syndrome of the premature infant.
D000328:Adult; D000649:Amniocentesis; D000653:Amniotic Fluid / Q000378:metabolism; D001663:Bilirubin / Q000378:metabolism; D002250:Carbon Radioisotopes; D004899:Erythroblastosis, Fetal / Q000378:metabolism; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control*; D014556:Urine / Q000032:analysis
D002250:Carbon Radioisotopes; D010713:Phosphatidylcholines; D001663:Bilirubin
Fallstudie zur Plazentargängigkeit von 14C-markiertem Lezithin